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Background: The opportunities for examining elderly patients with hepatocellular carci-
noma (HCC) have increased. We investigated the treatment of HCC for elderly patients and 
the overall survival associated with each treatment modality.
Methods: From January 2003 to December 2005 (n=578, period I) and January 2008 to 
December 2014 (n=2428, period II), the National Cancer Center and Korean Liver Cancer 
Association collected clinical data of 3006 patients with HCC aged ≥70 years old at 54 
medical centers in Korea. We analyzed the treatment modalities and overall survival for 
patients with HCC aged ≥70 years.
Results: The mean age, Child-Pugh score, and model for end-stage liver disease score and 
proportion of male patients were not different between period I and period II (74 years, 6.6, 
10.4 and 70.1% vs 76 years, 6.2, 9.9 and 67.3%). TNM stage II and BCLC stage A were 
most commonly noted in periods I and II (44.3% and 49.1% vs 40.4% and 40.2%). 
Transarterial therapy was the most commonly used treatment modality according to age in 
both periods. Surgical resection was associated with significant superior overall survival 
compared to local ablation and transarterial therapy (p<0.001). After propensity score 
matching between surgical resection and transarterial therapy in period II, surgical resection 
was associated with more favorable overall survival outcomes (median: 39 months vs 86 
months, p<0.001).
Conclusion: Transarterial therapy was the most commonly used treatment modality for 
patients with HCC aged ≥70 years. However, surgical resection led to significantly higher 
overall survival rates compared to other treatment modalities.
Keywords: hepatocellular carcinoma, elderly, surgical resection, transarterial therapy, local 
ablation therapy
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer and second 
leading cause of cancer related death worldwide.1,2 In South Korea, HCC is third 
most common cancer among gastrointestinal malignancy and the associated mor-
tality rate (14.1%) was the second highest among all cancer-related deaths in 2016.3 
The population in South Korea, like that in any other developed country in the 
world, has rapidly aged.4 Among patients who died owing to HCC in 2014, 67.4% 
of the patients were aged > 60 years and 28.5% of the patients were aged 70–79 
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years.5 It is well known that age is a contributing factor in 
the development of HCC.6,7
It is difficult to define “elderly patients”. Despite the 
ambiguity of the term, it is universally accepted that 
patients with a chronological age > 65 years are defined 
as “elderly patients”. With respect to the socioeconomic 
perspective, such patients are on the verge of retirement. 
The United Nations and the World Health Organization 
define individuals aged > 60 years as “elderly”.8 In most 
practical clinical studies, individuals who are “60 years 
old”, “65 years old”, or “70 years old” are defined as 
“elderly”.9 In the 1980s, researchers mainly defined the 
age of 65 years as “elderly”; however, the age of 75 years 
was defined as “elderly” in 90s. In studies involving 
a Japanese group, individuals aged > 80 years were 
defined as the “super-elderly population”.10–13
In previous studies on elderly patients with HCC in 
South Korea, researchers defined “elderly patient” as 
patients aged > over 65 or 70 years and investigated the 
treatment modalities and outcomes. However, these studies 
were confined to single centers, and it was difficult to reflect 
the trends or the outcomes of treatment in elderly patients 
with HCC nationwide using these data.14–16 To overcome 
these limitations and to aid in establishing a nationwide 
treatment strategy for elderly patients with HCC, we aimed 
to evaluate the therapeutic modalities used to treat patients 
with HCC aged > 70 years in detail and to compare the 
overall survival associated with each treatment modality 
using data from the National Cancer Center (NCC) and the 
Korean Liver Cancer Association (KLCA).
Patients and Methods
The Korean Central Cancer Registry
The Korean Central Cancer Registry (KCCR), a nationwide 
cancer registry, was developed by the Ministry of Health and 
Welfare, South Korea. Using code C22.0, which defines HCC, 
of the International Classification of Disease 10th edition 
(ICD-10) coding system, patients with HCC were identified 
in the KCCR registry. From January 2003 to December 2005 
(period I) and January 2008 to December 2014 (period II), the 
NCC and KLCA collected the clinical data of 3006 patients 
with HCC aged > 70 years from 54 medical centers in South 
Korea archived in the KCCR. New patients are enrolled in the 
cancer registry each year.
During 2003–2005 (period I), the KLCA collected the 
medical data from each tertiary medical center in South 
Korea. During that period, patients’ medical records from 
each medical center were voluntarily added in the database 
as the initial prototype of the cancer registry. After three 
years of preparation, the KCCR was started in collabora-
tion with the NCC, and medical recorders were dispatched 
to each medical center to collect the patient data.
Study Population and Study Design
Using these data, we analyzed the rates of use of and 
overall survival associated with each treatment modality 
for patients with HCC aged > 70 years. All the treatment 
modality is recorded as “initial treatment” for the patients. 
We obtained the patients’ mortality data from the Korean 
National Statistics Office (KNSO). The initial treatment 
dates and dates of disease progression were obtained from 
the KCCR records. To investigate the nationwide distribu-
tion of each treatment modality, we divided the patients 
into three groups (ages 70–75 years, aged 76–80 years, 
and aged > 80 years). The follow-up durations were esti-
mated from the date of initial treatment to date of death or 
were calculated to a certain date for each period 
(December 31, 2011 for period I and December 31, 2016 
for period II) for the analysis of overall survival.
In this study, the treatment modalities were classified as 
surgical resection, local ablation therapy, transarterial therapy, 
chemotherapy, radiation therapy, no treatment, and unknown. 
Local ablation therapy included radiofrequency ablation 
(RFA), percutaneous ethanol injection, and cryoablation. 
Transarterial therapy included transarterial chemoemboliza-
tion (TACE) with gelatin sponge, TACE with DC Beads™ 
(Biocompatibles Ltd, Farnham, UK) or HepaSphere™ 
(Biosphere Medical, Rockland, MA), transarterial chemoli-
piodolization, transarterial chemoinfusion, and transarterial 
radioembolization (Yt-90). We retrospectively reviewed the 
medical records of each patient. This study was approved by 
the internal review board of Severance Hospital (IRB No. 
4-2018-0354) and conducted according to the principles of 
the Declaration of Helsinki. Informed consent was obtained 
by the NCC and KLCA, and the collection of data was 
approved by each participating medical center or institution.
Statistical Analysis and Propensity Score 
Matching (PSM)
Descriptive analyses of the clinical data were performed 
using the Student’s t-test and Pearson’s chi-square test. 
The overall survival time was analyzed using the Kaplan- 
Meier method, and statistical differences were verified 
using Log rank tests. Statistical significance was set at 
https://doi.org/10.2147/JHC.S306507                                                                                                                                                                                                                                   
DovePress                                                                                                                                             
Journal of Hepatocellular Carcinoma 2021:8 322
Rho et al                                                                                                                                                              Dovepress
p<0.05. All results were reported as the mean with stan-
dard deviation or percentages. Propensity score matching 
(PSM) was performed, with the caliper set at 0.2. To 
reduce selection bias and the effects of potential confoun-
ders, the propensity score was calculated using logistic 
regression based on age, sex, etiology, Child-Pugh score, 
and Barcelona Clinic Liver Cancer (BCLC) stage. 
Differences between the two groups were balanced using 
1:1 PSM analysis. All statistical analyses were performed 
using SPSS® for Windows version 22.0 (IBM Corp., 
Armonk, NY, USA) and R version 3.3.1 (The R Project, 
Vienna, Austria).
Results
Clinical Characteristics in Patients with 
HCC
Period I included 578 patients with a mean age of 74 
years. Of the patients included in this period, 405 
(70.1%) were men, 152 (26.3%) had hepatitis B, and 
162 (28.0%) had hepatitis C. The mean Child-Pugh 
score (CPS) was 6.6, and the mean model for end- 
stage liver disease (MELD) score was 10.4. More than 
60% of the patients were classified as having Child- 
Pugh class A disease and 256 patients (44.3%) were 
classified as having TNM stage II stage, while 160 
patients (27.7%) were classified as having TNM stage 
III disease. Nearly half of the patients were classified as 
having BCLC stage A disease (284 patients; 49.1%); 93 
(16.1%), BCLC stage B disease; and 129 (22.3%), 
BCLC stage C disease.
Period II included 2428 patients with a mean age of 76 
years. Of the patients included in this period, 1633 (67.3%) 
were men, 587 (24.2%) had hepatitis B, and 552 (22.7%) 
had hepatitis C. The mean alpha-fetoprotein (AFP) level was 
5817 ± 876 ng/mL, and the mean protein induced by vitamin 
K absence or antagonist-II (PIVKA-II) level was 5208 ± 550 
mAu/mL. The mean CPS was 6.2, and the mean MELD 
score was 9.9. This period included 980 patients (40.4%) 
classified as having TNM stage II disease and 692 patients 
(28.5%) with TNM stage III disease. The BCLC classifica-
tion of the patients was as follows: 977 patients (40.2%), 
stage A disease; 382 patients (15.7%), stage B disease; and 
775 patients (32.0%), stage C (Table 1).







Age 74 ± 4 76 ± 5
Gender, male:female 405:173 (70.1:29.9) 1633:795 (67.3:32.7)
BMI (kg/m2) Not checked 23.4 ± 3.5
Etiology (%)
HBV 152 (26.3) 587 (24.2)
HCV 162 (28.0) 552 (22.7)
HBV and HCV 5 (0.9) 18 (0.7)
Alcohol 77 (13.3) 464 (19.1)
Unknown 182 (31.5) 807(33.2)
Diabetes Not checked 822 (33.9)
Hypertension Not checked 1299 (53.5)









None 557 (96.4) 2360 (97.1)
Grade 1–2 13 (2.2) 60 (2.5)
Grade 3–4 8 (1.4) 9 (0.4)
Ascites (%)
None 401 (69.4) 1830 (75.4)
Slight 112 (19.4) 369 (15.2)
Moderate to severe 65 (11.2) 229 (9.4)
AFP (ng/mL) Not checked 5817 ± 876
PIVKA-II (mAu/mL) Not checked 5208 ± 550
Child-Pugh score 6.6 ± 1.8 6.2 ± 1.5
Child-Pugh 
classification
A 357 (61.8) 1625 (66.9)
B 177 (30.6) 594 (24.5)
C 44 (7.6) 98 (4.0)
Unknown 111 (4.6)
MELD score 10.4 ± 4.2 9.9 ± 4.0
(Continued)
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Treatment Distribution According to Age
Transarterial therapy was the most commonly used treat-
ment modality for patients in period I (n=284 patients, 
49.1%). This treatment modality was used in 52.8% of 
the patients aged 70–75 years, 43.3% of the patients aged 
76–80 years, and 38.3% of the patients aged > 80 years. 
Surgical resection and local ablation therapy were each 
used in 6.3% of the patients aged 70–75 years.
Transarterial therapy was the most commonly used treat-
ment modality for patients in period II (n=1079 patients, 
44.4%). This treatment modality was used in 47.1% of the 
patients aged 70–75 years and 34.0% of the patients aged > 
80 years. Surgical ablation was used in 14.5% of the patients 
aged 70–75 years and 3.7% of the patients aged > 80 years. 
Among patients aged 70–75 years, 281 patients (20.2%) did 
not receive treatment, while 179 patients (47.2%) aged > 80 
years did not receive treatment (Table 2).
Overall Survival Analysis According to 
Treatment Modality
The overall survival was significantly longer for patients 
who underwent surgical resection in period I (n=29, med-
ian survival: 81 months) than that for those who under-
went local ablation therapy (n=41, median survival: 45 
months) and transarterial therapy (n=284, median survival: 
23 months; p<0.001; Figure 1).






I 35 (6.0) 285 (11.7)
II 256 (44.3) 980 (40.4)
III 160 (27.7) 692 (28.5)
IV-A 52 (9.0) 238 (9.8)
IV-B 49 (8.5) 223 (9.2)
Unknown 26 (4.5) 9 (0.4)
BCLC stage
0 25 (4.3) 132 (5.4)
A 284 (49.1) 977 (40.2)
B 93 (16.1) 382 (15.7)
C 129 (22.3) 775 (32.0)
D 47 (8.2) 162 (6.7)
Note: Data are reported as mean ± standard deviation or n (%). 
Abbreviations: HBV, hepatitis B; HCV, hepatitis C; ECOG, Eastern Cooperative 
Oncology Group; AFP, alpha-fetoprotein; PIVKA-II, proteins induced by vitamin 
K absence or antagonist-II; MELD, model for end-stage liver disease; BCLC, 
Barcelona clinic liver cancer; BMI, body mass index.
Table 2 Treatment Distribution According to Age
A. Period I (2003–2005)
Treatment Modality Total (N=578) Age
70–75 (N=379) 76–80 (N=152) >80 (N=47) p-value
Surgical resection 29 (5.0) 24 (6.3) 4 (2.6) 1 (2.1) 0.119
Local ablation therapy 41(7.1) 24 (6.3) 12 (7.9) 5 (10.6)
Transarterial therapy 284 (49.1) 200 (52.8) 66 (43.4) 18 (38.3)
Systemic chemotherapy 1 (0.2) 1 (0.3) 0 (0) 0 (0)
Radiation therapy 7 (1.2) 4 (1.1) 3 (2.0) 0 (0)
Unknown 216 (37.4) 126 (33.2) 67 (44.1) 23 (48.9)
B. Period II (2008–2014)
Treatment Modality Total (N=2428) Age
70–75 (N=1393) 76–80 (N=656) >80 (N=379) p-value
Surgical resection 255 (10.5) 202 (14.5) 39 (5.9) 14 (3.7) 0.159
Local ablation therapy 255 (10.5) 167 (12.0) 66 (10.1) 22 (5.8)
Transarterial therapy 1079 (44.4) 655 (47.1) 295 (45.0) 129 (34.0)
Systemic chemotherapy 88 (3.6) 48 (3.4) 24 (3.7) 16 (4.2)
Radiation therapy 22 (0.9) 12 (0.9) 7 (1.1) 3 (0.8)
No treatment 667 (27.5) 281 (20.2) 207 (31.6) 179 (47.2)
Unknown 62 (2.6) 28 (2.0) 18 (2.7) 16 (4.2)
Note: Data are reported as mean ± standard deviation or n (%).
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The overall survival was significantly longer for 
patients who underwent surgical resection (n=255, median 
survival: 88 months; p<0.001) in period II than for those 
who received other therapeutic modalities, followed by 
local ablation therapy (n=255, median survival: 64 
months), transarterial therapy (n=1079, median survival: 
Figure 1 Overall survival according to the treatment modality used in period I (2003–2005). The overall survival was significantly longer for patients who underwent 
surgical resection in period I than that for those who underwent local ablation therapy and transarterial therapy.
Figure 2 Overall survival according to the treatment modality used in period II (2008–2014). The overall survival was significantly longer for patients who underwent 
surgical resection in period II than for those who received other therapeutic modalities, followed by local ablation therapy, transarterial therapy, radiation therapy, and 
systemic chemotherapy.
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27 months), radiation therapy (n=22, median survival: 7 
months), and systemic chemotherapy (n=88, median sur-
vival: 4 months; Figure 2). Among 88 patients who 
received systemic therapy including sorafenib, 66 patients 
were categorized as BCLC C. In the BCLC C category, 57 
patients treated by sorafenib as initial therapy for the HCC.
Subgroups Analysis of Overall Survival 
According to BCLC Stage and Treatment 
Modality in Each Period
The overall survival according to the BCLC stage in 
both periods was significantly longer in the order of 
BCLC stage 0, A, B, C and D. Between each stage, 
there were statistically significant differences. In the 
comparison of median survival at the same BCLC 
stages in both periods, there was no significant differ-
ences in BCLC stage D. However, in the early stage of 
HCC especially BCLC stage 0 and A, the median sur-
vival of period II increased more than 10 months com-
pared to period I. (BCLC stage 0: 63 months vs 53 
months) (BCLC stage A: 37 months vs 27 months) 
(Supplement Figure S1, Supplement Figure S2). In the 
subgroup analysis of overall survival according to 
BCLC stage and treatment modality in each period, 
more various treatments were attempted even in the 
advanced stage such BCLC stage C and D in period II 
compared to period I. (Supplement Figure S3, 
Supplement Figure S4).
PSM Between Surgical Resection and 
Transarterial Therapy
After 1:1 PSM, 247 patients who underwent surgical resection 
were matched with 247 patients who underwent transarterial 
therapy. There were no significant differences with respect to 
age, gender, etiology, performance status, AFP level, PIVKA- 
II level, CPS, TNM stage and BCLC stage between the 
surgical resection and transarterial therapy groups. Only the 
MELD score (8.6) of the transarterial therapy group was 
significantly higher than that of the surgical resection group 
(8.0; p=0.012). TNM stage II was most common in both 
groups (surgical resection: 73.3%; transarterial therapy: 
68.8%). Stage O was the most common BCLC stage in both 
groups (surgical resection: 61.1%; transarterial therapy: 
57.9%; Table 3). Survival analysis after PSM revealed that 
the overall survival was significantly longer for patients who 
underwent surgical resection (median survival: 86 months) 
than the matched patients who underwent transarterial therapy 
(median survival: 39 months; p<0.005; Figure 3).
Table 3 Clinical Characteristics After Propensity Score Matching 








Age 74 ± 4 74 ± 3 0.910
Gender, 
male
183 (74.1) 193 (78.1) 0.342
Etiology 0.899
HBV 62 (25.1) 67 (27.1)
HCV 46 (18.6) 50 (20.2)
HBV and 
HCV
1 (0.4) 2 (0.8)
Alcohol 55 (22.3) 51 (20.6)




0 151 (61.1) 153 (61.9)
1 41 (16.6) 22 (8.9)
2 5 (2.0) 6 (2.4)
Unknown 50 (20.2) 50 (20.2)
AFP (ng/mL) 1806 ± 831 2102 ± 741 0.791
PIVKA 
(mAu/mL)
3253 ± 688 2812 ± 733 0.662
Child-Pugh 
score
5.3 ± 0.7 5.3± 0.6 0.684
MELD score 8.0± 2.2 8.6± 2.3 0.012
TNM Stage 0.512
Stage I 18 (7.3) 19 (7.7)
Stage II 182 (73.3) 170 (68.8)
Stage III 42 (17.0) 51 (20.6)
Stage IV-A 2 (0.8) 5 (2.0)
Stage IV-B 3 (1.2%) 2 (0.8)
BCLC stage 0.087
O 151 (61.1) 143 (57.9)
A 41 (16.6) 35 (14.2)
B 54 (21.9) 68 (27.5)
C 1 (0.4) 1 (0.4)
D 0 (0) 0 (0)
Note: Data are reported as mean ± standard deviation or n (%). 
Abbreviations: HBV, hepatitis B; HCV, hepatitis C; ECOG, Eastern Cooperative 
Oncology Group; AFP, alpha-fetoprotein; PIVKA-II, proteins induced by vitamin 
K absence or antagonist-II; MELD, model for end-stage liver disease; BCLC, 
Barcelona clinic liver cancer.
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PSM Between Surgical Resection and 
Local Ablation Therapy in Early HCC
After PSM, 87 patients of surgical resection and local 
ablation therapy were compared, respectively. Only 
patients in BCLC stage 0 and A were included. There 
were no significant differences in terms of age, gender, 
etiology, performance status, AFP level, MELD score 
(Table 4). In overall survival analysis after PSM, there 
was a significant benefit for patients who underwent sur-
gical resection (median survival: 88 months) than the 
patients who underwent local ablation therapy (median 
survival: 65 months, p=0.036) (Figure 4).
Prognostic Factors in Each Period
In the univariate and multivariate cox-regression analysis 
of overall survival, the BCLC stage and treatment modal-
ity were significant prognostic factors in both periods. In 
period I, female, hepatitis C infection and hepatic ence-
phalopathy were significant prognostic factors. Whereas, 
old age, AFP, PIVKA level, and the high Child-Pugh score 
were poor prognostic factors for overall survival in period 
II. (Table 5).
Discussion
As patients age, the risk of drug-induced injuries, critical 
viral hepatitis, and intra-abdominal sepsis in the liver 
increases.17 The incidence of HCC in elderly patients 
reflects these risks. Hepatitis is the most potent predispos-
ing factor for HCC, and the incidence of hepatitis 
C among patients aged > 60 years has increased rapidly 
in South Korea.18 The incidence of non-hepatitis B- and 
non-hepatitis C-related HCC (NBNC-HCC) is also signif-
icantly higher among the elderly patients. Katsuta et al 
reported that the incidence of NBNC-HCC is significantly 
higher in patients aged > 80 years than in younger 
patients.10 In elderly patients, HCC frequently develops 
in the normal liver without cirrhosis or fibrosis. Paradis 
et al reported that the incidence of HCC without liver 
fibrosis was higher in patients with metabolic syndrome 
than in those with chronic liver injuries due to other 
causes.19 Satyanarayana et al and Plentz et al have both 
reported that shortened telomere lengths owing to aging 
deplete the ability to regenerate the liver and that liver 
cirrhosis and loss of P53 accelerate the telomere dysfunc-
tion, resulting in the development of HCC.20,21
Knowledge of these pathophysiological changes in the 
liver is important when treating HCC in elderly patients. 
Most importantly, the risks and benefits of any treatment 
modality should be assessed prior to administering it to the 
elderly patients with HCC. The benefit of the treatment 
should be greater than the decrease in survival owing to 
the treatment and maladjustments resulting from physical 
or mental stress. As most elderly patients have comorbid-
ities, effective treatment strategies must be identified using 
Figure 3 Overall survival analysis after PSM between the two groups in period II (2008–2014). Survival analysis after PSM revealed that the overall survival was significantly 
longer for patients who underwent surgical resection than the matched patients who underwent transarterial therapy.
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a more systematic approach that includes the evaluation of 
rehabilitation and long-term care.
In this study, we identified the rate of use of different 
therapeutic modalities and the changes noted in the thera-
peutic modalities used for treating HCC in elderly patients 
over time. In period I, only 5.0% of the patients underwent 
surgical resection, and unspecified modalities (including no 
treatment) were used for 37.4% of the patients. In period II, 
10.5% of the patients underwent surgical resection, and 
unspecified methods (including no treatment) were used for 
only 30.1% of the patients. This shift indicates that biologi-
cal age is not the only factor used to determine the indication 
for aggressive treatment. However, in patients aged > 80 
years, the rate of use of unspecified methods (including no 
treatment) was stable (period I: 48.9%; period II: 51.4%).
Kaplan-Meier analysis revealed that the longest overall 
survival was noted for patients who underwent surgical 
resection, followed by patients who underwent local abla-
tion therapy and transarterial therapy. In the subgroup 
analysis of overall survival according to BCLC stage and 
treatment modality in each period, BCLC stage 0 and 
A showed better survival with statistical significance com-
pared to other advanced stages in both periods. In addition, 
more various treatment modalities were attempted in per-
iod II compared to period I, the median survival increased 
by more than 10 months in early BCLC stages (0 and A).
PSM was performed to compare the therapeutic effects 
between the surgical resection group, which is considered 
the most radical treatment, and the transarterial therapy 
group, which is the most widely used treatment modality 
for elderly patients. Surgical resection was associated with 
a statistically significant overall survival benefit compared 
to transarterial therapy. Furthermore, in overall survival 
analysis of early HCC including BCLC stage 0 and 
A only, surgical resection showed statistically significant 
benefit compared to local ablation therapy after PSM. 
There is still a debating the issue in terms of treating the 
small early HCC by local ablation therapy.22–26 This pre-
sent study supported the evidence that surgical resection is 
preferred in treating the small early HCC even in elderly 
patients. This is probably due to several reasons. First, this 
database included all anatomical resection and non- 
anatomical resection. Second, because surgical methods 
well-established recently, perioperative mortality of the 
“elderly patients” was extremely low. In addition, unlike 
the SURF trial, this study is only focused on only “elderly 
patients”. Thus, it is possible that more “healthy patients” 
who cannot be subdivided by ECOG performance criteria 
had become candidates for surgical resection.
In the analysis of prognostic factors for overall survi-
val, the BCLC stage and treatment modality were signifi-
cant commonly in both periods. The old age, AFP, PIVKA 
level, and the high Child-Pugh score were poor prognostic 
factors in period II. These are the same prognostic factors 
that affect the overall survival even in the general popula-
tion group as well as elderly patients.
According to the Korea Practice Guideline for the 
Management of HCC, surgical resection is the primary 
treatment for solitary HCC without liver cirrhosis and for 
patients with cirrhosis who are expected to have sufficient 
residual liver function after surgical resection.27 In elderly 
patients, resection should be considered carefully, as the 
capacity for liver regeneration is compromised. Currently, 
detailed guidelines are not available for the treatment of 
HCC in elderly patients, although several studies have 
Table 4 Clinical Characteristics After Propensity Score Matching 
Between Surgical Resection and Local Ablation Therapy for Early 







Age 73.8 ± 3.6 74.0 ± 3.7 0.695
Gender, male 60 (69.0%) 61 (70.1%) 1.000
Etiology 0.603
HBV 25 (28.7%) 20 (23.0%)
HCV 19 (21.8%) 26 (29.9%)
Alcohol 17 (19.5%) 18 (20.7%)
Unknown 26 (29.9%) 23 (26.4%)
ECOG performance 0.862
0 64 (73.6%) 66 (75.9%)
Unknown 23 (26.4%) 21 (24.1%)




A 84 (96.6%) 82 (94.3%)
B 3 (3.4%) 5 (5.7%)
MELD score 7.9 ± 1.6 8.1 ± 1.7 0.440
BCLC stage 0.654
O 10 (11.5%) 13 (14.9%)
A 77 (88.5%) 74 (85.1%)
Note: Data are reported as mean ± standard deviation or n (%). 
Abbreviations: HBV, hepatitis B; HCV, hepatitis C; ECOG, Eastern Cooperative 
Oncology Group; AFP, alpha-fetoprotein; MELD, model for end-stage liver disease; 
BCLC, Barcelona clinic liver cancer.
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reported comparable outcomes of surgical resection in 
elderly HCC patients. In many studies, aggressive treat-
ment, such as surgical resection, is beneficial for elderly 
patients without critical comorbidities, such as cardiovas-
cular disease. Iida et al compared the outcomes of 44 
patients with HCC aged > 80 years and 351 patients with 
HCC aged < 80 years who underwent surgical resection 
and found no significant differences between the two 
groups with respect to the overall or disease-free survival. 
However, postoperative complications were found to sig-
nificantly affect the overall survival of the patients aged 
>80 years in multivariate regression analysis (Nutrient 
status was identified potent cause of postoperative compli-
cations, and the authors emphasized on perioperative nutri-
tional support.11 Kim et al reported that the incidence of 
postoperative pneumonia was significantly higher in 
patients aged >70 years old than in patients aged 60–69 
years.28 Kishida et al also reported that the postoperative 
complication rate (≥ Clavien-Dindo classification grade 
III) was significantly higher in patients aged > 75 years 
old compared patients aged < 75 years old.29 Kaibori et al 
used data from the Liver Cancer Study Group of Japan to 
analyze the overall survival of 12,587 patients with HCC 
who underwent hepatectomy. The patients were divided 
into three groups (aged > 75 years: 2020 patients; aged 
60–74 years: 7576 patients; and aged 40–59 years: 2991 
patients). They found that the overall survival of patients 
aged > 75 years was significantly lesser than that of the 
patients in the other groups but that the disease-free survi-
val of the three groups was not significantly different.30 
Therefore, limited resection should be performed in con-
sideration of the regeneration capacity of the liver. 
Perioperative nutritional support should be provided and 
efforts should be made to prevent the development post-
operative infections.
When surgical resection cannot be performed, RFA and 
TACE are the good alternative therapeutic strategies. 
Previous studies compared the overall survival of patients 
aged > 75 years and patients aged < 75 years who under-
went RFA and found no significant difference in the over-
all survival between the two matched groups.31,32 Yau et al 
reported that the disease-free specific survival was signifi-
cantly longer in patients aged > 70 years who underwent 
TACE than in those aged < 70 years who underwent 
TACE).33 In contrast, Mirici-Cappa et al found no signifi-
cant differences in the overall survival between patients 
aged > 70 years and patients aged < 70 years who were 
matched using PSM.34 These studies indicate that RFA 
Figure 4 Overall survival analysis after PSM between surgical resection and radiofrequency ablation groups for early stage hepatocellular carcinoma in period II 
(2008–2014). Survival analysis after PSM revealed that the overall survival was significantly longer for patients who underwent surgical resection than the matched patients 
who underwent local ablation therapy. 
Abbreviation: PSM, propensity score matching.
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and TACE are effective modalities for treating HCC in 
elderly patients. However, clinicians should not overlook 
the procedure-related complications, such as infections 
and bleeding, associated with RFA and vessel injury 
owing to age related atherosclerosis and contrast induced 
renal dysfunction in TACE.35
There are some limitations of this study. First, data 
were not available regarding liver transplantation, which 
is being implemented as a fundamental treatment for HCC. 
Second, data on specific findings, such as HCC location or 
surgical method and operation type, were also not avail-
able. Third, the data for disease-free survival were incom-
plete. Fourth, data for the treatment method and cause of 
HCC were incomplete for several patients included in this 
study. A more comprehensive national database, which 
includes detailed findings for all patients, is needed for 
conducting similar studies in the future.
As advanced countries move towards a super-aged 
society, the number of elderly patients with HCC is 
expected to increase. With the recent improvement in 
the outcomes of antiviral treatment, the mortality rate 
associated with liver cirrhosis is likely to decrease. As 
the rate of chronic viral infections of the liver increases 
among elderly patients, the rate of HCC will also 
increase. Clinicians must be aware of the balance 
between survival benefits and postoperative complica-
tions and exacerbation of comorbidities, when consid-
ering aggressive treatment for elderly patients with 
HCC. Aggressive treatments, such as surgical resec-
tion, can be performed in elderly patients only after 
Table 5 Multivariate Cox-Regression Analysis in Each Period
Period I Period II
Variables p-value HR 95% CI p-value HR 95% CI
Age 0.167 1.019 0.992–1.046 0.004 1.026 1.009–1.044
Gender (female) 0.018 0.771 0.621–0.955 0.460 1.072 0.891–1.289
HCV 0.007 0.734 0.586–0.920 0.310 0.094 0.744–1.099
Child- Pugh score 0.609 1.034 0.910–1.15 0.002 1.204 1.070–1.354
MELD score 0.089 1.031 0.995–1.067 0.121 1.018 0.995–1.042
BCLC stage
0 Ref. Ref.
A 0.318 1.295 0.780–2.148 0.405 1.191 0.790–1.795
B 0.041 1.764 1.024–3.040 0.015 1.729 1.111–2.689
C 0.006 2.168 1.255–3.745 0.005 1.832 1.201–2.794
D 0.031 2.263 1.076–4.760 0.024 1.941 1.090–3.456
Hepatic encephalopathy
None Ref. Ref.
Gr 1–2 0.005 2.356 1.298–4.276 0.253 0.702 0.382–1.288
Gr 3–4 0.072 2.116 0.936–4.786 0.359 0.868 0.756–1.112
AFP 0.022 1.380 0.993–2.213
PIVKA <0.001 1.259 0.893–1.983
Treatment
Surgical resection Ref. Ref.
Local ablation therapy 0.003 2.830 1.411–5.677 0.023 1.593 1.067–2.379
Transarterial therapy <0.001 3.556 1.934–6.539 <0.001 2.701 1.994–3.658
Systemic chemotherapy 0.021 11.68 1.460–93.506 <0.001 9.287 6.123–14.085
Radiation therapy <0.001 16.307 6.020–44.173 <0.001 4.659 2.201–9.860
No treatment N/A <0.001 7.213 5.107–10.186
<Unknown <0.001 6.481 3.438–12.218 <0.001 6.673 3.212–13.865
Abbreviations: BMI, body mass index; HBV, hepatitis B; HCV, hepatitis C; AFP, alpha-fetoprotein; PIVKA-II, proteins induced by vitamin K absence or antagonist-II; MELD, 
model for end-stage liver disease; BCLC, Barcelona clinic liver cancer; BMI, body mass index.
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the careful and comprehensive evaluation of the 
patient’s condition.
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